IBD Guts Fail to Clear Oxalate, Worsening Inflammation — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UNC Chapel Hill researchers found that two oxalate transporter proteins (SLC26A2 and SLC26A3) were consistently present at lower levels in intestinal tissue from patients with both ulcerative colitis and Crohn's disease, and the more inflamed the tissue, the lower the transporter expression tended to be
- Crohn's disease patients had significantly higher stool oxalate levels than people without IBD despite consuming similar amounts of plant-based foods, a finding confirmed through both the Diet History Questionnaire III and DNA metabarcoding — the first time the molecular method was used to evaluate diet in an IBD population
- Mice given oxalate-supplemented diets alongside a colitis-inducing substance were 60% less likely to survive than mice without extra dietary oxalate, and in two genetically susceptible mouse models, dietary oxalate caused colitis to appear sooner and become more severe
- Low expression of the SLC26A6 transporter was associated with stricturing Crohn's disease — the more aggressive scarring form — with nearly 75% of patients showing reduced expression affected, raising the possibility of a biomarker for severe disease (though researchers stress this needs confirmation in larger cohorts)
- Cell culture experiments showed oxalate intensified inflammatory responses in macrophages and dendritic cells, immune cells that regulate intestinal protection
- Oxalobacter formigenes and related gut bacteria that break down oxalate are less abundant in people with IBD, suggesting future microbiome-based treatments could improve oxalate clearance as an alternative to dietary restriction
Why it matters: For people with Crohn's disease and ulcerative colitis, this reframes the diet-inflammation link: it's not just what they eat but how their gut processes oxalate that appears to worsen disease. The stricturing Crohn's finding — nearly 75% of patients with low SLC26A6 expression — hints at a potential biomarker for flagging patients at risk of aggressive disease progression.
Ask SkimNews
